News
Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-DMPK Rx to Treat Myotonic Dystrophy Type 1
Isis Earns $14 Million Milestone Payment from Biogen Idec ISIS-DMPKRx is the Second Generation 2.5 Antisense Drug to Enter the Clinic Isis Pharmaceuticals, Inc....
News
Biotech Stocks Technical Report — Research on Exact Sciences, Anacor Pharma, Cubist Pharma, and Agenus
On Friday, June 06, 2014, the NASDAQ Composite ended at 4,321.40, up 0.59%, the Dow Jones Industrial Average finished the day 0.52% higher at...
News
Immune Design starts dosing patients in Phase I study of LV305 immuno-oncology agent
US-based Immune Design has started dosing patients in a Phase I clinical study of LV305, an immuno-oncology investigational agent from its DCVex lentiviral vector...
Press Releases
State-owned British research institute fund Clinical trial of Airsonett – an innovative Swedish asthma treatment
There are 5 million persons suffering from asthma in Great Britain and despite medication, half a million of these persons have symptoms which limit...
News
Edge Therapeutics begins enrolment in second cohort of EG-1962 Phase I/II trial for aSAH
US-based biotechnology firm Edge Therapeutics has started enrolling patients in the second group of a multicenter, randomised, controlled, open-label, Phase I/II NEWTON trial of...
Press Releases
Point of Care Set to Boom in Coming Years; Driving Forward Quality and Maximising Efficiency
The global market for Point of Care diagnostics is set to sharply increase by 2018 and Europe’s market is becoming increasingly competitive due to...
Press Releases
The Orphan Drugs Market is set to Rise as a Result of Pharma Companies now Looking to Orphan Drugs as an Essential...
As of January 2014, the EMA lifted the restriction on providing fee reductions to large companies developing new orphan drugs and the Early Access...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read